A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Kara L DavisElizabeth FoxEmasenyie IsikweiJoel M ReidXiaowei LiuCharles G MinardStephan D VossStacey L BergBrenda J WeigelCrystal L MackallPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The RP2D of nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) is well tolerated in children and young adults with solid tumors and shows some clinical activity. Increased dose of ipilimumab (3 mg/kg) plus nivolumab (1 mg/kg) was associated with increased toxicity without clinical benefit.